---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-21-000171"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T15:08:11.302190+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evolus Q3 revenue $26.7M (+58% YoY); record sales; initiates extra-strength Jeuveau Phase II

## Summary
- U.S. net revenue of $26.7M, up 58% YoY; total net revenue up 51% to $26.7M.
- GAAP operating loss $19.1M vs. $8.8M YoY; non-GAAP operating loss $14.3M vs. $6.5M.
- Cash $107.8M at Sept 30, down from $131.7M due to $15M milestone payment.
- Initiated Phase II for extra-strength Jeuveau; first patient expected Q1 2022, completion 1H 2023.
- Accounts purchasing Jeuveau increased by 500 to >6,500; loyalty program doubled to 240,000 registrants.

## SEC filing metadata
- accession: 0001570562-21-000171
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056221000171/0001570562-21-000171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056221000171/eols-20211102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-21-000171
- JSON: https://secwatch.observer/filing/0001570562-21-000171.json
- Plain text: https://secwatch.observer/filing/0001570562-21-000171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.